Your session is about to expire
← Back to Search
Pulmonary rehabilitation program + EA Lung Mu-Shu+ St36 for Chronic Obstructive Pulmonary Disease
N/A
Recruiting
Led By James E Stahl, MD, CM, MPH
Research Sponsored by Dartmouth-Hitchcock Medical Center
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Patients must be 18 years of age or older
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up baseline, 4 weeks, 8 weeks, 12 weeks, and 16 weeks
Awards & highlights
Study Summary
This trial is investigating whether acupuncture could improve symptoms and quality of life for patients with COPD.
Who is the study for?
This trial is for adults over 18 with Chronic Obstructive Pulmonary Disease (COPD) who qualify for a pulmonary rehab program. It's not suitable for those with severe cognitive issues, unstable heart/lung conditions, or active worsening of lung symptoms.Check my eligibility
What is being tested?
The study tests if acupuncture can boost the benefits of standard pulmonary rehabilitation in COPD patients. Two types of acupuncture treatments are being compared alongside regular rehab exercises.See study design
What are the potential side effects?
Acupuncture may cause minor side effects like soreness, bruising at needle sites, and rare instances of bleeding or infection. The pulmonary rehab itself typically has minimal risks.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowSelect...
I am 18 years old or older.
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ baseline, 4 weeks, 8 weeks, 12 weeks, and 16 weeks
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~baseline, 4 weeks, 8 weeks, 12 weeks, and 16 weeks
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Primary outcome measures
Change in 6-minute walk distance
Change in Forced expiratory volume in one second (FEV1)
Change in Forced vital capacity (FVC)
+7 moreTrial Design
3Treatment groups
Experimental Treatment
Group I: Arm C: 4 week intervention, 16 week controlExperimental Treatment2 Interventions
Electro acupuncture (EA) intervention will be administered for 4 weeks to the Lung Mu-Shu points and St36 which are related to lung function and general function. The EA control intervention will be administered for 16 weeks and will use Lv7 and Gb 26 which are near the other points but not traditionally related to lung function or general function.
Group II: Arm B: 8 week intervention, 12 week controlExperimental Treatment2 Interventions
Electro acupuncture (EA) intervention will be administered for 8 weeks to the Lung Mu-Shu points and St36 which are related to lung function and general function. The EA control intervention will be administered for 12 weeks and will use Lv7 and Gb 26 which are near the other points but not traditionally related to lung function or general function.
Group III: Arm A: 12 week intervention, 8 week controlExperimental Treatment2 Interventions
Electro acupuncture (EA) intervention will be administered for 12 weeks to the Lung Mu-Shu points and St36 which are related to lung function and general function. The EA control intervention will be administered for 8 weeks and will use Lv7 and Gb 26 which are near the other points but not traditionally related to lung function or general function.
Find a Location
Who is running the clinical trial?
Dartmouth-Hitchcock Medical CenterLead Sponsor
524 Previous Clinical Trials
2,543,309 Total Patients Enrolled
American Academy of Medical AcupunctureUNKNOWN
James E Stahl, MD, CM, MPHPrincipal InvestigatorDartmouth-Hitchcock Medical Center
Media Library
Eligibility Criteria:
This trial includes the following eligibility criteria:- I am eligible for the pulmonary rehab program at DHMC.My heart or lung condition is not stable.I am currently experiencing a worsening of my lung condition.I am 18 years old or older.I have significant memory or thinking problems.
Research Study Groups:
This trial has the following groups:- Group 1: Arm A: 12 week intervention, 8 week control
- Group 2: Arm B: 8 week intervention, 12 week control
- Group 3: Arm C: 4 week intervention, 16 week control
Awards:
This trial has 1 awards, including:- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
Timeline:
This trial has the following timeline:- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Does this research endeavor still have open enrollment?
"As revealed on clinicaltrials.gov, the recruitment stage for this medical trial was concluded after it's initial launch in October 2022 and final edit in August of the same year. Although they are not presently searching for candidates, 271 other studies are actively looking to enrol patients at present."
Answered by AI
Recent research and studies
Other Trials to Consider
Popular Categories
Share this study with friends
Copy Link
Messenger